Even after a tumor has been removed and a patient is in remission, tiny traces of cancer can still remain in the bloodstream. Without knowing just how many of those cells remain, oncologists may under ...

Veracyte (Nasdaq: VCYT) announced it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) detection ...

C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India. Cancer rates in India are an epidemic on the rise; from 2010 to 2019, cancer ...

While many of the companies currently developing blood tests to help diagnose cancer or track the disease’s progression are churning out physical tests that can be sent out to labs and hospitals ...

Karkinos Healthcare, a technology-driven cancer care platform in India, has entered into a strategic partnership with American oncology diagnostics firm C2i Genomics to promote AI-enabled cancer ...

C2i Genomics, a New York, NY-based cancer intelligence company, launched its C2inform minimal residual disease (MRD) test across Europe after snagging CE-IVD marking in the European Union, the United ...

If you or a loved one has ever undergone a tumor removal as part of cancer treatment, you’re likely familiar with the period of uncertainty and fear that follows. Will the cancer return, and if so, ...